1. BPMC management to present at Needham Virtual Healthcare Conference on April 7. 2. Live webcast available; replay archived for 30 days. 3. Company focuses on allergy, inflammation, and oncology/hematology treatments. 4. BPMC aims to expand its pipeline in mast cell diseases and cancers. 5. Track record includes two approved medicines, enhancing company credibility.
Upcoming conference participation raises visibility and investor interest. Similar events previously led to price increases for biopharmaceutical companies, particularly post-announcements of advancements or collaborations.
High potential for investor engagement and market positioning contributes to stock value. The successful presentation of company strategies may influence short-term trading.
Immediate effects expected from conference presentation. Past conferences led to short-term stock fluctuations due to investor reactions.
CAMBRIDGE, Mass., March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 12:45 p.m. ET.
A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities.
We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors.
For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.